Prothena Corp Public (PRTA) Income towards Parent Company (2012 - 2026)
Prothena Corp Public's (PRTA) quarterly Income towards Parent Company came in at $32.7 million in Q1 2026, up 154.36% year-on-year from $12.9 million in Q1 2025, and up 251.89% quarter-over-quarter from -$21.5 million in Q4 2025.
Prothena Corp Public (PRTA) Income towards Parent Company (2012 - 2026) Analysis & Trends
Prothena Corp Public's Income towards Parent Company history runs 15 years deep, the most recent figure standing at $32.7 million for Q1 2026.
- On a quarterly basis, Income towards Parent Company rose 154.36% year-over-year to $32.7 million in Q1 2026; TTM through Mar 2026 was -$151.1 million, a 36.91% decrease from a year earlier, with the FY2025 full-year figure at -$244.1 million, down 99.57% from the prior year.
- Income towards Parent Company improved to $32.7 million in Q1 2026 per PRTA's latest filing, from -$21.5 million in the prior quarter.
- Across five years, Income towards Parent Company topped out at $66.8 million in Q2 2024 and bottomed at -$125.8 million in Q2 2025.
- The 5-year median for Income towards Parent Company is -$45.7 million (2022), against an average of -$35.2 million.
- Across the five-year window, Income towards Parent Company slumped 1162.78% in 2023 and jumped 222.43% in 2024, its largest moves.
- Year by year, Income towards Parent Company stood at $6.3 million in 2022, then slumped by 1162.78% to -$67.5 million in 2023, then rose by 14.07% to -$58.0 million in 2024, then soared by 62.85% to -$21.5 million in 2025, then jumped by 251.89% to $32.7 million in 2026.
- Per Business Quant, the three latest PRTA Income towards Parent Company figures stand at $32.7 million (Q1 2026), -$21.5 million (Q4 2025), and -$36.5 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Prothena Corp Public | 471.02 Mn | 141.56 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 32.72 Mn |
| Dec 31, 2025 | -21.54 Mn |
| Sep 30, 2025 | -36.51 Mn |
| Jun 30, 2025 | -125.77 Mn |
| Mar 31, 2025 | -60.20 Mn |
| Dec 31, 2024 | -57.98 Mn |
| Sep 30, 2024 | -59.04 Mn |
| Jun 30, 2024 | 66.85 Mn |
| Mar 31, 2024 | -72.24 Mn |
| Dec 31, 2023 | -67.48 Mn |
| Sep 30, 2023 | 21.92 Mn |
| Jun 30, 2023 | -54.60 Mn |
| Mar 31, 2023 | -46.88 Mn |
| Dec 31, 2022 | 6.35 Mn |
| Sep 30, 2022 | -45.72 Mn |
| Jun 30, 2022 | -41.27 Mn |
| Mar 31, 2022 | -36.29 Mn |
| Dec 31, 2021 | -33.14 Mn |
| Sep 30, 2021 | 109.25 Mn |
| Jun 30, 2021 | 27.60 Mn |